

#### SAFE HARBOR STATEMENTS



#### **Cautionary Note Regarding Forward-Looking Statements**

This presentation contains forward-looking statements regarding the Company's future business expectations, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans, strategies and financial results, including expected improvement in gross profit and gross margin. All statements (other than statements of historical fact) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forwardlooking statements. These statements are often characterized by terminology such as "believe," "hope," "may," "anticipate," "should," "intend," "plan," "will," "expect," "estimate," "project," "positioned," "strategy" and similar expressions, and are based on assumptions and assessments made in light of our experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, including the following: adverse impacts of the global COVID-19 pandemic; laws and regulations regarding direct selling may prohibit or restrict our ability to sell our products in some markets or require us to make changes to our business model in some markets; extensive government regulations to which the Company's products, business practices and manufacturing activities are subject; legal challenges to the Company's direct selling program or to the classification of its independent distributors; impact of anti-bribery laws, including the U.S. Foreign Corrupt Practices Act; the Company's ability to attract and retain independent distributors; the loss of one or more key independent distributors who have a significant sales network; the Company's joint venture for operations in China with Fosun Industrial Co., Ltd.; registration of products for sale in foreign markets, or difficulty or increased cost of importing products into foreign markets; cybersecurity threats and exposure to data loss; the storage, processing, and use of data, some of which contain personal information, are subject to complex and evolving privacy and data protection laws and regulations; reliance on information technology infrastructure; the effect of fluctuating foreign exchange rates; liabilities and obligations arising from improper activity by the Company's independent distributors; failure of the Company's independent distributors to comply with advertising laws; changes to the Company's independent distributor compensation plans; geopolitical issues and conflicts; negative consequences resulting from difficult economic conditions, including the availability of liquidity or the willingness of the Company's customers to purchase products; risks associated with the manufacturing of the Company's products; uncertainties relating to the application of transfer pricing, duties, value-added taxes, and other tax regulations, and changes thereto; changes in tax laws, treaties or regulations, or their interpretation; actions on trade relations by the U.S. and foreign governments; product liability claims; the sufficiency of trademarks and other intellectual property rights; and our cannabidiol (CBD) product line is subject to varying, rapidly changing laws, regulations, and rules.

These and other risks and uncertainties that could cause actual results to differ from predicted results are more fully detailed under the caption "Risk Factors" in our reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports filed on Form 10-Q.

All forward-looking statements speak only as of the date of this presentation and are expressly qualified in their entirety by the cautionary statements included in or incorporated by reference into this presentation. Except as is required by law, the Company expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this presentation.

#### **Non-GAAP Financial Measures**

We have included information which has not been prepared in accordance with generally accepted accounting principles (GAAP), such as information concerning non-GAAP net income and Adjusted EBITDA. We utilize the non-GAAP measures of non-GAAP net income and Adjusted EBITDA in the evaluation of our operations and believe that these measures are useful indicators of our ability to fund our business. These non-GAAP financial measures should not be considered as an alternative to, or more meaningful than, U.S. GAAP net income (loss) as an indicator of our operating performance. Other companies may use the same or similarly named measures, but exclude different items, which may not provide investors with a comparable view of Nature's Sunshine Products' performance in relation to other companies. We have included a reconciliation of Net Income to Adjusted EBITDA, the most comparable GAAP measure. We have also included a reconciliation of GAAP net income to Non-GAAP net income and Non-GAAP Adjusted EPS, in the appendix. We believe presenting the impact of foreign currency fluctuations is useful to investors because it allows a more meaningful comparison of net sales of our foreign operations from period to period. Net sales excluding the impact of foreign currency fluctuations should not be considered in isolation or as an alternative to net sales in U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

#### NATURE'S SUNSHINE



# FEEL THE POWER...



Nature's Sunshine changed the world ~50 years ago as the first company to put herbs into easy-to-take capsules



We sell 800+ products across six different categories around the world



Sophisticated in-house R&D capabilities via owned Hughes Center for Research & Innovation



We manufacture most of our products, ensuring optimal quality and safety



We are executing a brand pivot supported by important consumer lifestyle changes

#### Q2 FINANCIAL SUMMARY



\$ in million, except for margin and per share amounts

	Q2 2023	Q2 2022	<b>A</b>	Q2 (y/y) Commentary
Net Sales	\$116.5	\$104.2	11.9%	Growth across most markets offset by impact of currency exchange; up 14.4% on a constant currency basis.
Gross Margin	72.6%	71.7%	+0.9%	Reflects improvements in market mix and lower costs for material, production, transportation and distribution, partially offset by unfavorable foreign currency exchange in Q2 2023.
SG&A	\$42.3	\$36.9	+14.7%	This increase was driven by increased service fees in China and higher costs related to implementation of business transformation and sales growth initiatives.
Operating Income	\$7.0	\$5.8	22.3%	Reflects the factors above.
Net Income <sup>1</sup>	\$2.4	\$0.5	+\$1.9	Reflects the Net Sales & SG&A factors as well as favorable income tax provisions compared to the prior-year quarter.
Diluted EPS	\$0.12	\$0.03	+\$0.09	Reflects the factors above.
Adj. EBITDA <sup>2</sup>	\$11.3	\$9.0	+25.9%	Reflects the factors above.

<sup>&</sup>lt;sup>1</sup> Attributable to common shareholders

<sup>&</sup>lt;sup>2</sup> See appendix for a reconciliation of non-GAAP terms.

#### STRONG BALANCE SHEET



#### **Balance Sheet Highlights**

- Cash and cash equivalents totaled \$69.0M
- \$0.5M of debt at 6/30/23 vs. \$1.2M at 12/31/22

	As	As of		
(\$ in millions)	Jun. 30, 2023	Dec. 31, 2022		
Cash and Cash Equivalents	\$ 69.0	\$ 60.0		
Receivables	12.5	14.1		
Total Assets	236.2	229.8		
Debt	0.5	1.2		
Total Liabilities	86.8	82.7		
Total Stockholders' Equity	149.4	147.0		

#### NET SALES BY OPERATING SEGMENT




	Net Sales by Operating Segment (Amounts in Thousands)						
	Q2 2023	Q2 2022	% Change	Impact of Currency Exchange	% Change Excl. Impact of Currency		
Asia	\$ 54,875	\$ 47,382	15.8%	\$ (2,806)	21.7%		
Europe	21,236	17,099	24.2	233	22.9		
North America	34,658	34,082	1.7	(136)	2.1		
Latin America and Other	5,779	5,598	3.2	110	1.3		
	<u>\$ 116,548</u>	<u>\$ 104,161</u>	11.9%	<u>\$ (2,609)</u>	14.4%		

#### HISTORICAL FINANCIAL PERFORMANCE



#### Revenue

\$ in Millions




#### **Revenue Accelerant Opportunities**

- Stronger regional-focused sales teams
- International market growth (Taiwan and Japan)
- Increased productivity of customers & distributors
- New products

#### Adj. EBITDA<sup>1</sup>

\$ in Millions



#### **Margin Drivers**

- Raw material optimization
- Drive manufacturing efficiencies, removing waste
- Logistics and transportation efficiencies
- SG&A cost efficiencies

<sup>&</sup>lt;sup>1</sup> See appendix for a reconciliation of this non-GAAP term.


#### **OUR OPERATIONAL EXECUTION**



#### **Brand Power**



#### **Field Energy**



#### **Digital First**



#### **Manufacturing Inc.**







Revitalized our brand with new packaging & advertising

Offered new suite of business tools, services & customer-focused rewards

Introduced new website functionality to move from transactional to personal relationships Secured USDA and ISO 9001 certifications, enhancing our industryleading advantage Streamlined global business processes to improve overall cost and efficiency

# 2023 PRIORITIES



# OUR RESPONSE TO TODAY'S CONSUMER DEFINES OUR VISION



# Vision

SHARE THE HEALING POWER OF NATURE, WITH EVERYONE.

#### How?



Offer specialty, time-tested products, proven by health practitioners



**Create lifestyle** branding and storytelling




Leverage websites, e-commerce and digital marketing to drive customer loyalty



Deliver customized experiences to encourage trial and repeat purchases

#### OUR FIVE GLOBAL GROWTH STRATEGIES





#### CAPITAL ALLOCATION PLAN



Significant cash flow has enabled the investment and growth of the business to date

Well-positioned to return a portion of this cash to shareholders

#### **Capital Allocation Plan**

\$0.9M in shares repurchased at an average cost of \$9.28 per share in 1H 2023 - \$23.1M remaining in share repurchase program as of June 30, 2023

Investment in process improvement and supply chain

Ongoing investment in organic growth opportunities

Strategic M&A



## **CONTACT US**

Investor Relations Contact

### **Cody Slach**

Senior Managing Director, Gateway Group, Inc.



(949) 574-3860



NATR@gatewayir.com

# **APPENDIX**



#### ADJUSTED EBITDA RECONCILIATION



	Three Months Ended June 30.			
	2	023	2022	
Net income (loss)	\$	2,677	\$	952
Adjustments:				
Depreciation and amortization		2,833		2,685
Share-based compensation expense		1,437		540
Other (income) loss, net*		1,087		442
Provision for income taxes		3,273		4,361
Other adjustments				_
Adjusted EBITDA	\$	11,307	\$	8,980

<sup>\*</sup>Other (income) loss, net is primarily comprised of foreign exchange losses, interest income, and interest expense.

#### ADJUSTED EBITDA RECONCILIATION



	RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA					
		2019	2020	2021	2022	Q2'23 TTM
Net Income (loss)	\$	6,929	\$ 22,958	\$ 30,207	\$ 550	\$ 6,214
Adjustments:						
Depreciation and amortization		10,599	10,743	11,162	11,025	11,212
Share-based compensation expense		2,120	3,787	3,731	2,901	4,055
Other (income) loss, net*		483	(1,339)	2,848	1,043	(140)
Provision (benefit) for income taxes		8,713	(137)	1,615	14,665	10,329
Other adjustments (1)		2,375	173	(143)	1,846	3,637
Adjusted EBITDA	\$	31,219	\$ 36,185	\$ 49,420	\$ 32,030	\$ 35,307
(1) Other Adjustments						
Capital allocation and other unusual expenses		-	-	265	-	-
Inventory reserve related to Russia/Ukraine war**		-	-	-	1,000	(2,050)
Charge related to Japan loss		-	-	-	-	5,847
Restructuring related expenses		2,375	808	369	587	330
Loss on sale of properties		-	-	-	1,069	1,069
VAT Refund		-	(635)	(777)	(810)	(1,559)
Total adjustments	\$	2,375	\$ 173	\$ (143)	\$ 1,846	\$ 3,637

<sup>\*</sup>Other (income) loss, net is primarily comprised of foreign exchange losses, interest income, and interest expense.